GB1300567A - Therapeutic compositions - Google Patents

Therapeutic compositions

Info

Publication number
GB1300567A
GB1300567A GB6217269A GB6217269A GB1300567A GB 1300567 A GB1300567 A GB 1300567A GB 6217269 A GB6217269 A GB 6217269A GB 6217269 A GB6217269 A GB 6217269A GB 1300567 A GB1300567 A GB 1300567A
Authority
GB
United Kingdom
Prior art keywords
virus
particles
mould
animal
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6217269A
Inventor
Donald Noel Planterose
Michael Sidney Verrall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Priority to GB6217269A priority Critical patent/GB1300567A/en
Publication of GB1300567A publication Critical patent/GB1300567A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1300567 Anti-viral material from Penicillium stoloniferum BEECHAM GROUP Ltd 9 Dec 1970 [20 Dec 1969] 62172/69 Heading A5B Animals other than human beings are protected against virus infection by administering to the animal a composition consisting of or comprising virus-like particles obtained from the mould Penicillium stoloniferum. Preferably the composition contains both virus-like particles and free double-stranded ribonucleic acid or a salt thereof, said RNA being obtained from the virus-like particles of the mould Penicillium stoloniferum. The compositions may be administered topically or by systemic injection to the animal before it becomes infected with the infective virus and may be administered on repeated occasions during the period when the animal is susceptible to infection. Protection has been achieved in a variety of animals, e.g. against Coxsackie B1 virus, Semliki Forest virus, vaccinia virus, foot and mouth disease virus, vesicular stomatitis virus, rabies virus and influenza virus. Virus-like particles having antiviral activity can be extracted from a medium in which the mould Penicillium stoloniferum has been grown by separating the mycelium of the mould from a culture medium in which it has been grown, treating the culture medium with RNA or a salt thereof, adjusting the pH of the resulting liquor to a pH of 3 to 6, separating the resulting precipitate from the supernatant, concentrating and purifying a suspension of the precipitate, e.g. by ultrafiltration and differential sedimentation, to yield the virus-like particles. Double-stranded RNA can be extracted from the virus-like particles so obtained by deproteinisation.
GB6217269A 1969-12-20 1969-12-20 Therapeutic compositions Expired GB1300567A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB6217269A GB1300567A (en) 1969-12-20 1969-12-20 Therapeutic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB6217269A GB1300567A (en) 1969-12-20 1969-12-20 Therapeutic compositions

Publications (1)

Publication Number Publication Date
GB1300567A true GB1300567A (en) 1972-12-20

Family

ID=10487927

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6217269A Expired GB1300567A (en) 1969-12-20 1969-12-20 Therapeutic compositions

Country Status (1)

Country Link
GB (1) GB1300567A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427098A1 (en) * 1978-06-03 1979-12-28 Boehringer Sohn Ingelheim PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427098A1 (en) * 1978-06-03 1979-12-28 Boehringer Sohn Ingelheim PREPARATIONS BASED ON RIBONUCLEIC TRANSFER ACIDS, WITH ANTIVIRAL ACTIVITY

Similar Documents

Publication Publication Date Title
WO2001019380A3 (en) Oncolytic virus
EP0025719A3 (en) Gamma-globulin preparation for intravenous administration, process for production thereof and process for preparation of gamma-globulin of low anticomplementary activity
BG86132A (en) PYRIDAZINAMINE DERIVATIVES
ATE20309T1 (en) PHARMACEUTICAL PREPARATION.
DE2435746C2 (en)
Kern et al. Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid
GB1300567A (en) Therapeutic compositions
JPS5676401A (en) Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
US4049794A (en) Treatment of infections in animals
Carroll et al. Resistance of visna virus to interferon
BE760760A (en) NEW DERIVATIVES OF 9-AZOLYL-FLUORENE-9-CARBOXYLIC ACID, THEIR PROCESS OF PREPARATION AND THEIR APPLICATION TO THE REGULATION OF PLANT GROWTH
CA2258675A1 (en) 2-cyclopenten-1-one as an inducer of hsp70
GB1187830A (en) Pharmaceutical Compositions comprising Polynucleotides
JPS6120525B2 (en)
ES350690A1 (en) Concentration and purification of influenza viruses
US3952103A (en) Herpes viral infection treatment
IE32044B1 (en) Process for the manufacture of a tetanus-vaccine
IE32015L (en) Producing interferon inducer
Hashimoto et al. The Mode of Production of Endotoxin‐Induced Interferon in Rabbit Tissue Cells: I. Development of Priming by Pretreatment with Interferon
GB1300259A (en) Biologically active material
SU1522486A1 (en) Method of preparing of substance showing hepatoprotective activity
RU2012352C1 (en) Antivirus composition
Furusawa et al. Antiviral activity of tobacco leaf on encephalomyocarditis (EMC) virus infection
USD228051S (en) Study carrel
GB1254744A (en) Antiviral ribonucleic acid substance

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees